Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nilutamide

FDA-approved product (tablet, oral), marketed as Nilandron, Nilutamide.

Registered studies
14
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Nilutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anti-androgens
FDA pharmacologic class
Androgen Receptor Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli20.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

14registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nilutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nilutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

    NCT04787744 · start 2021-07-01

    Registered record
    Registry ID
    NCT04787744
    Conditions
    Prostate Cancer; Oligometastasis; Oligorecurrence; Recurrent Prostate Cancer; Metastatic Prostate Cancer; De Novo Prostate Cancer
    Interventions
    PET-directed Local Therapy using Surgery; PET-directed Local Therapy using Radiation; Salvage Local Therapy for locally recurrent disease; Goserelin, Histrelin, Leuprolide & Triptorelin; ADT + Nilutamide, Flutamide, & Bicalutamide; Degarelix & Relugolix; ADT + Docetaxel +/- prednisone; ADT + Abiraterone + Prednisone; ADT + Abiraterone + Methylprednisolone; ADT + Apalutamide; ADT + Enzalutamide; Prostate-directed Radiation for De novo oligometastatic prostate cancer
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2021-07-01
    Completion
    2029-03-30
    Enrolment
    464

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Oligometastasis; Oligorecurrence; Recurrent Prostate Cancer +2 more
    InterventionPET-directed Local Therapy using Surgery; PET-directed Local Therapy using Radiation; Salvage Local Therapy for locally recurrent disease; Goserelin, Histrelin, Leuprolide & Triptorelin +8 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

    NCT03678025 · start 2018-09-24

    Registered record
    Registry ID
    NCT03678025
    Conditions
    Castration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Abiraterone; Bicalutamide; Degarelix; Docetaxel; Flutamide; Goserelin Acetate; Histrelin Acetate; Leuprolide Acetate; Nilutamide; Orchiectomy; Prednisone; Quality-of-Life Assessment; Radiation Therapy; Radical Prostatectomy; Triptorelin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2018-09-24
    Completion
    2031-10-01
    Enrolment
    1,273

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8 +1 more
    InterventionAbiraterone; Bicalutamide; Degarelix; Docetaxel +11 more
    PhasePhase 3
    Registry statusRecruiting

  • Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

    NCT03070886 · start 2017-04-05

    Registered record
    Registry ID
    NCT03070886
    Conditions
    Stage I Prostate Adenocarcinoma AJCC v7; Stage II Prostate Adenocarcinoma AJCC v7; Stage III Prostate Adenocarcinoma AJCC v7
    Interventions
    Bicalutamide; Degarelix; Docetaxel; External Beam Radiation Therapy; Flutamide; Goserelin; Goserelin Acetate; Laboratory Biomarker Analysis; Leuprolide; Leuprolide Acetate; Nilutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2017-04-05
    Completion
    2030-10-31
    Enrolment
    612

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage I Prostate Adenocarcinoma AJCC v7; Stage II Prostate Adenocarcinoma AJCC v7; Stage III Prostate Adenocarcinoma AJCC v7
    InterventionBicalutamide; Degarelix; Docetaxel; External Beam Radiation Therapy +7 more
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients

    NCT02376296 · start 2015-02

    Registered record
    Registry ID
    NCT02376296
    Conditions
    Prostate Cancer
    Interventions
    docetaxel; Blood draws
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-02
    Completion
    2018-02-10
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventiondocetaxel; Blood draws
    PhaseNot recorded
    Registry statusCompleted

  • RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

    NCT02090114 · start 2014-08-25

    Registered record
    Registry ID
    NCT02090114
    Conditions
    Prostate Cancer
    Interventions
    Testosterone cypionate; Testosterone Enanthate; Abiraterone acetate; Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-08-25
    Completion
    2021-11-11
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionTestosterone cypionate; Testosterone Enanthate; Abiraterone acetate; Enzalutamide
    PhasePhase 2
    Registry statusCompleted

  • Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

    NCT01786265 · start 2013-02-05

    Registered record
    Registry ID
    NCT01786265
    Conditions
    Prostate Adenocarcinoma; Recurrent Prostate Carcinoma
    Interventions
    Abiraterone Acetate; Bicalutamide; Degarelix; Flutamide; Goserelin Acetate; Leuprolide Acetate; Nilutamide; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2013-02-05
    Completion
    2027-02-01
    Enrolment
    310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma; Recurrent Prostate Carcinoma
    InterventionAbiraterone Acetate; Bicalutamide; Degarelix; Flutamide +4 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

    NCT00918385 · start 2009-05

    Registered record
    Registry ID
    NCT00918385
    Conditions
    Prostate Cancer
    Interventions
    Nilutamide; Dasatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-05
    Completion
    2013-08
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionNilutamide; Dasatinib
    PhasePhase 2
    Registry statusTerminated

  • Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer

    NCT00512668 · start 2007-09

    Registered record
    Registry ID
    NCT00512668
    Conditions
    Adenocarcinoma of the Prostate; Recurrent Prostate Cancer
    Interventions
    leuprolide acetate; goserelin acetate; bicalutamide; nilutamide; flutamide; temsirolimus; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2007-09
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Prostate; Recurrent Prostate Cancer
    Interventionleuprolide acetate; goserelin acetate; bicalutamide; nilutamide +3 more
    PhasePhase 1
    Registry statusTerminated

  • Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy

    NCT00175396 · start 2004-05

    Registered record
    Registry ID
    NCT00175396
    Conditions
    Prostate Cancer
    Interventions
    Androgen suppression, radiotherapy; Androgen suppression, radiotherapy, iodine 125 brachytherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2004-05
    Completion
    2014-06
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionAndrogen suppression, radiotherapy; Androgen suppression, radiotherapy, iodine 125 brachytherapy
    PhasePhase 3
    Registry statusUnknown

  • S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

    NCT00028769 · start 2001-12

    Registered record
    Registry ID
    NCT00028769
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide; estramustine; etoposide; flutamide; goserelin; leuprolide; nilutamide; paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-12
    Completion
    2011-07
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide; estramustine; etoposide; flutamide +4 more
    PhasePhase 2
    Registry statusCompleted

  • Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

    NCT00020254 · start 2000-06

    Registered record
    Registry ID
    NCT00020254
    Conditions
    Prostate Cancer
    Interventions
    aldesleukin; recombinant fowlpox-prostate specific antigen vaccine; recombinant vaccinia prostate-specific antigen vaccine; recombinant vaccinia-B7.1 vaccine; sargramostim; nilutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2000-06
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionaldesleukin; recombinant fowlpox-prostate specific antigen vaccine; recombinant vaccinia prostate-specific antigen vaccine; recombinant vaccinia-B7.1 vaccine +2 more
    PhasePhase 2
    Registry statusCompleted

  • Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

    NCT00003653 · start 1999-01-05

    Registered record
    Registry ID
    NCT00003653
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide; buserelin; cyproterone acetate; flutamide; goserelin; leuprolide acetate; nilutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-01-05
    Completion
    2013-01-10
    Enrolment
    1,386

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide; buserelin; cyproterone acetate; flutamide +3 more
    PhasePhase 3
    Registry statusCompleted

  • Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

    NCT00002855 · start 1996-08

    Registered record
    Registry ID
    NCT00002855
    Conditions
    Prostate Cancer
    Interventions
    Bicalutamide; Doxorubicin hydrochloride; Estramustine Phosphate Sodium; Flutamide; Ketoconazole; Nilutamide; Therapeutic Hydrocortisone; Vinblastine; Conventional Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1996-08
    Completion
    2005-06
    Enrolment
    306

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionBicalutamide; Doxorubicin hydrochloride; Estramustine Phosphate Sodium; Flutamide +5 more
    PhasePhase 3
    Registry statusCompleted

  • Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

    NCT00002633 · start 1995-02-08

    Registered record
    Registry ID
    NCT00002633
    Conditions
    Prostate Cancer
    Interventions
    bicalutamide; buserelin; flutamide; goserelin; leuprolide acetate; nilutamide; orchiectomy; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-02-08
    Completion
    2012-01-06
    Enrolment
    361

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionbicalutamide; buserelin; flutamide; goserelin +4 more
    PhasePhase 3
    Registry statusCompleted